UNSPSC 51111639: Fazarabine

This classification denotes a pyrimidine antagonist with the molecular formula C8H12N4O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5V71D8JOKK, chemically known as 1,3,5-triazin-2 (1h)-one, 4-amino-1-.beta.-d-ribofuranosyl- but generally known as fazarabine, which bears US NIH Compound Identifier 1805. European Medicines Agency schedules Fazarabine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07517MIG.

UNSPSC 51111639 Fazarabine is a Commodity code covering a specific pharmaceutical product. Recent state and local activity under this code centers on pharmacy benefit program design and pharmaceutical supply chain management rather than direct procurement of the drug itself. The Texas Health and Human Services Commission issued a Request for Information (RFI) in April 2026 seeking vendor capabilities for a Therapeutic Pharmacy Initiative (TPI) Direct-to-Manufacturer Prescriptions program—an exploratory solicitation designed to evaluate how state agencies and self-insured health plans can establish direct contracting relationships with pharmaceutical manufacturers outside traditional pharmacy benefit managers, group purchasing organizations, and wholesalers. The RFI solicits vendor experience with direct contracting for self-insured employers and state health plans, flexibility to negotiate net pricing models without rebates, and capacity to implement value-based or outcomes-based agreements. This is preliminary market intelligence rather than a competitive bid; no award values, budget allocations, or set-aside designations are specified at the RFI stage.

State health and human services departments driving pharmaceutical procurement strategy appear to be the primary issuing bodies under this code. Geographic activity is currently limited to Texas, with the TPI Direct-to-Manufacturer program representing exploratory procurement activity that will likely inform a formal RFP with defined financial and temporal parameters once the state completes its vendor-capability assessment. The RFI response deadline of April 3, 2026 has passed; vendors pursuing pharmaceutical supply relationships with state HHS agencies should monitor Texas HHS Commission procurement channels for follow-on formal solicitations that will establish explicit pricing, volume, and performance expectations based on vendor responses to this foundational information-gathering phase.